# GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

> **NCT06077903** · EARLY_PHASE1 · TERMINATED · sponsor: **Grit Biotechnology** · enrollment: 10 (actual)

## Conditions studied

- Adult

## Interventions

- **BIOLOGICAL:** GT101

## Key facts

- **NCT ID:** NCT06077903
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-05
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** The study was terminated from a business perspective.
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06077903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06077903, "GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06077903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*